FRAGMENT 176-191 2mg

Fragment 176-191 is a synthetic analog of human growth hormone (hGH). This peptide consists of the 16 amino acids from the C-terminus of the hGH peptide, spanning positions 176-191. The substitution of tyrosine with phenylalanine at position 191 enhances the peptide’s ability to break down lipids.¹ With a molecular weight of 1812 g/mol, Fragment 176-191 mimics the function of growth hormone-releasing factor (GHRF), also known as growth hormone-releasing hormone (GHRH), which stimulates the pituitary gland to release growth hormone (GH).²

Lipolytic Properties

Often referred to as the “lipolytic fragment,” Fragment 176-191 promotes fat loss. Studies on genetically engineered mice with larger fat stores have shown that the peptide enhances fat loss by binding to beta-3 adrenergic receptors (ADRB3) in adipose tissue. In contrast, fat loss effects were not observed in mice lacking ADRB3, confirming the receptor’s crucial role in this process.³ Additionally, the peptide induces thermogenesis in skeletal muscle, contributing to an increased basal metabolic rate.⁴

Diabetes Study

Other studies suggest that Fragment 176-191 may help regulate blood sugar levels by gradually increasing insulin secretion, thereby lowering blood sugar in animal models. This has garnered interest in its potential as a therapeutic agent for diabetes.⁵

Support for Cartilage Regeneration

Fragment 176-191 may also support cartilage regeneration. Weekly administration, both alone and in conjunction with hyaluronic acid, has shown promise in enhancing cartilage regeneration. In a rabbit model of osteoarthritis, Fragment 176-191 reduced disability when administered either alone or alongside hyaluronic acid.⁶

Product Information

Fragment 176-191 is supplied as a lyophilized white powder at a concentration of 2 mg/vial.

Important Notice

This product is intended for in vitro laboratory research use only. It is not approved for human or veterinary use under any circumstances.

References

1. Habibullah MM, Mohan S, Syed NK, et al. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther. 2022;16:1963-1974.
2. Harvey S, Martinez-Moreno CG. Growth Hormone: Therapeutic Possibilities—An Overview. Int J Mol Sci. 2018;19(7):2015.
3. Heffernan M, Summers RJ, Thorburn A, et al. The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β₃-AR Knock-Out Mice. Endocrinology. 2001;142(12):5182-9.
4. Ferrer-Lorente R, Cabot C, Fernandez-Lopez J, Alemany M. Combined Effects of Oleoyl-Estrone and a Beta3-Adrenergic Agonist (CL316,243) on Lipid Stores of Diet-Induced Overweight Male Wistar Rats. Life Sci. 2005;77(16):2051-8.
5. Ng FM, Bornstein J. Hyperglycemic Action of Synthetic C-Terminal Fragments of Human Growth Hormone. Am J Physiol. 1978;234(5):E521-6.
6. Kwon DR, Park GY. Effect of Intra-Articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-32.